Upcoming Webinar:

Scaling Up Oral Solid Dose Manufacturing for Late-Phase Success

Share this webinar

Description

As your programme advances to Phase 2b or Phase 3, new challenges emerge: larger batch sizes, tighter process controls, and heightened regulatory expectations.

In this webinar, our experts will share strategies for successful OSD scale-up and how to select a CDMO partner that can seamlessly take you from clinical to commercial manufacturing.

What You’ll Gain:

Practical insights to streamline the transition from early-phase to late-phase development.
Proven approaches to controlling scale-sensitive steps—blending, granulation, compression, and coating—essential for consistent quality and performance.
Guidance on building a robust, validation-ready process that supports commercial readiness and future success.

We’ll also explore how partnering with a single-site CDMO that integrates development and GMP manufacturing can shorten timelines and reduce complexity.

This session is ideal for biotech companies evaluating CDMOs to support oral solid drug product development.

Our Speakers

Dipak brings over a decade of hands-on experience in drug product development and manufacturing. At Upperton Pharma Solutions, he leads clinical-scale production and scale-up initiatives from Phase 1 through late-stage trials. His expertise spans formulation development, technical transfer, equipment qualification, and commercial readiness. Dipak holds a BSc in Pharmaceutical & Cosmetic Science from De Montfort University and is completing his PhD in Pharmaceutical Sciences at the University of Nottingham.

Nathan serves as Lead Principal Scientist at Upperton Pharma Solutions, specializing in technical transfer and scale-up of pharmaceutical dosage forms. With a Chemistry degree from the University of Glasgow and more than a decade of experience, he guides analytical method transfer and process implementation for early-to-late-stage clinical programs.

Key Challenges Addressed

Late-phase OSD hurdles: process robustness, material variability, and equipment selection.
Leveraging QbD and DoE data to inform late-phase design.
Scaling from lab to late-phase manufacturing.

What You'll Learn

Why CDMO selection is critical for late-stage scale-up.
How early planning prevents delays and accelerates timelines.
Translating lab data into robust, scalable processes using QbD principles.

Register now

Unlock the potential of nasal drug delivery for Central Nervous System (CNS) therapies in this expert-led webinar. With increasing focus on non-invasive routes and the promise of direct nose-to-brain transport, the nasal pathway presents both exciting opportunities and complex challenges. We’ll explore the strategic considerations behind developing drug products for CNS delivery via nasal routes, focusing especially on the critical role of device selection.

Key topics covered

Understanding of barriers to successful brain/CNS delivery: Blood-brain barrier.
The benefits and challenges of Nose to Brain (N2B) Delivery.
Delivery Targets and Transport Mechanisms for Nose to Brain (N2B) Delivery.
Developing nasal dosage forms.
Liquid v Dry Powder and Formulation Considerations.
Device Considerations for Nose to Brain (N2B) delivery.
Practical insights into device testing methods including AINI